New Insights Link Untreated Sleep Apnea to Elevated Parkinson’s Risk, Highlighting the Protective Role of CPAP Therapy

Recent clinical findings have cast new light on the critical intersection between respiratory health and neurodegeneration, revealing that individuals suffering from untreated obstructive sleep apnea (OSA) face a significantly heightened vulnerability to developing Parkinson’s disease. Published on November 24 in JAMA Neurology, a landmark retrospective study demonstrates that managing this common sleep disorder through continuous positive airway pressure (CPAP) therapy can substantially mitigate that risk. By maintaining a steady flow of oxygen and preserving restorative sleep architectures throughout the night, medical interventions for sleep apnea may offer a vital layer of neurological protection as patients age.

The comprehensive investigation was spearheaded by a dedicated team of researchers from Oregon Health & Science University (OHSU) and the Portland VA Health Care System. To arrive at their conclusions, the scientific team conducted an exhaustive analysis of electronic health records drawn from an expansive cohort of more than 11 million U.S. military veterans. These individuals received comprehensive medical care through the Department of Veterans Affairs across a twenty-three-year timeline spanning from 1999 to 2022. The sheer magnitude of this dataset affords the study a remarkable statistical power, allowing researchers to control for confounding variables and establish robust correlations that have eluded smaller, less diverse epidemiological projects.

Understanding the Growing Threat of Parkinson’s Disease

Parkinson’s disease remains one of the most prevalent and debilitating progressive neurological disorders worldwide. In the United States alone, the condition currently affects an estimated 1 million individuals. Clinically characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability, the disease arises from the progressive degeneration of dopamine-producing neurons in the substantia nigra region of the brain. Epidemiological data indicates that the likelihood of developing this neurodegenerative condition grows progressively each year, particularly after an individual reaches the age of 60.

As global populations age, identifying modifiable risk factors has become a paramount objective for the neurological research community. While genetic predispositions and environmental toxins have long been recognized as primary contributors to Parkinson’s pathology, lifestyle and physiological factors that compromise cerebral health over decades are receiving heightened scrutiny. The latest research from the OHSU and Portland VA teams strongly suggests that long-term, untreated obstructive sleep apnea belongs firmly in this category of modifiable risk factors, serving as a chronic physiological stressor that may accelerate neurodegenerative processes.

Methodological Rigor and Statistical Findings

To isolate the specific impact of untreated sleep apnea on Parkinson’s disease incidence, the research team implemented rigorous statistical adjustments. The investigators accounted for a wide array of confounding variables historically linked to both sleep disorders and neurodegeneration, including advanced age, obesity, tobacco use, and high blood pressure. Even after neutralizing the statistical noise introduced by these critical health indicators, a clear, unmistakable association persisted between untreated sleep apnea and the subsequent diagnosis of Parkinson’s disease.

Among the millions of veterans evaluated within the dataset who suffered from sleep apnea, those who failed to utilize CPAP therapy were nearly twice as likely to receive a Parkinson’s diagnosis compared to individuals who consistently adhered to the treatment. This dramatic disparity underscores the profound therapeutic potential of managing nighttime respiratory disturbances.

Co-author Dr. Gregory Scott, M.D., Ph.D., an assistant professor of pathology in the OHSU School of Medicine and a staff pathologist at the Portland VA, contextualized these findings for patients. "It’s not at all a guarantee that you’re going to get Parkinson’s, but it significantly increases the chances," Dr. Scott explained, emphasizing that while sleep apnea is not a singular cause of the disease, its role as a major risk amplifier cannot be overlooked.

Cellular Mechanisms: How Sleep Apnea Damages the Brain

To comprehend why correcting sleep apnea might protect against neurodegeneration, researchers must examine the immediate physiological consequences of the disorder. Obstructive sleep apnea is characterized by recurrent episodes of complete or partial upper airway obstruction during sleep. These episodes lead to repeated pauses in breathing, known as apneas, and shallow breathing phases, known as hypopneas. Each interruption triggers acute drops in blood oxygen saturation levels, frequently accompanied by micro-arousals that disrupt the normal, restorative architecture of human sleep.

The brain is an exceptionally metabolically active organ with a relentless demand for oxygen. When systemic oxygen levels plummet repeatedly throughout the night, cellular respiration is compromised. Lead author Dr. Lee Neilson, M.D., an assistant professor of neurology at OHSU and a staff neurologist at the Portland VA, elaborated on this cellular vulnerability.

"If you stop breathing and oxygen is not at a normal level, your neurons are probably not functioning at a normal level either," Dr. Neilson stated. "Add that up night after night, year after year, and it may explain why fixing the problem by using CPAP may build in some resilience against neurodegenerative conditions, including Parkinson’s."

Over decades, this chronic intermittent hypoxia and sleep fragmentation induce systemic inflammation, oxidative stress, and vascular dysregulation—pathological hallmarks that create an environment highly conducive to protein misfolding and neuronal death.

Implications for Clinical Practice and Patient Care

The publication of these findings is anticipated to reshape clinical protocols across neurology, pulmonology, and primary care settings. Traditionally, obstructive sleep apnea has been treated primarily to alleviate daytime fatigue, improve cardiovascular health, and reduce the risk of hypertension, stroke, and metabolic disorders. The revelation that untreated OSA significantly elevates the risk of Parkinson’s disease introduces an entirely new dimension to patient counseling.

Dr. Neilson noted that the study’s conclusions have already altered his own approach to patient management. By framing sleep health not merely as a matter of daily energy levels and comfort, but as a critical safeguard against long-term cognitive and neurological decline, clinicians can provide a more compelling rationale for intervention. When patients understand that adhering to CPAP therapy may preserve their motor and cognitive faculties well into old age, compliance rates could see a meaningful improvement.

Patient experience with continuous positive airway pressure therapy varies, and initial adjustment periods can sometimes deter new users. However, Dr. Scott highlighted the overwhelmingly positive feedback reported by veterans who successfully incorporate the device into their nightly routines.

"The veterans who use their CPAP love it," Dr. Scott observed. "They’re telling other people about it. They feel better, they’re less tired. Perhaps if others know about this reduction in risk of Parkinson’s disease, it will further convince people with sleep apnea to give CPAP a try."

Comprehensive Research Collaboration and Funding Support

The depth and validity of the OHSU and Portland VA study are bolstered by a multidisciplinary team of investigators and robust institutional backing. In addition to Dr. Scott and Dr. Neilson, the research team included Isabella Montano, B.A., Dr. Jasmin May, M.D., Ph.D., Dr. Jonathan Elliott, Ph.D., and Dr. Miranda Lim, M.D., Ph.D., representing OHSU and the Portland VA Health Care System. Furthermore, the collaboration extended to institutions in Washington State, incorporating the expertise of Dr. Yeilim Cho, M.D., and Dr. Jeffrey Iliff, Ph.D., from the University of Washington and the VA Puget Sound Health Care System.

Conducting a retrospective epidemiological analysis of this scale required substantial financial resources and institutional infrastructure. The project received considerable support from the Department of Veterans Affairs through multiple competitive grant awards, including BX005760, CX00253, I01RX004822, I01RX005371, CX002022, BX006155, and Bx006155. Additional philanthropic and public sector backing was provided by the John and Tami Marick Family Foundation, the Collins Medical Trust, the National Institute on Aging of the National Institutes of Health (under award P30AG066518), and the U.S. Army Medical Research Acquisition Activity, located at Fort Detrick, Maryland, under award numbers HT9425-24-1-0774 and HT9425-24-1-0775.

The study’s authors formally noted that all opinions, interpretations, conclusions, and recommendations expressed within the publication are exclusively their own and do not necessarily reflect the official endorsements or policies of the Department of Defense, the National Institutes of Health, the Department of Veterans Affairs, or any other funding entity.

Broader Medical Analysis and Future Directions

The implications of the JAMA Neurology study extend far beyond the immediate demographic of military veterans. While the VA population provided an unusually rich, long-term dataset for analysis, the physiological mechanics linking intermittent hypoxia to neurodegeneration apply universally to human biology. As healthcare systems globally confront the rising tide of neurodegenerative diseases, prioritizing the diagnosis and aggressive treatment of sleep disorders emerges as a potent public health strategy.

Future research directions will likely focus on prospective clinical trials to observe whether initiating CPAP therapy in early-stage sleep apnea patients actively halts or reverses biomarkers associated with Parkinson’s disease. Additionally, investigators aim to explore whether treating sleep apnea can influence the progression rate in individuals who have already received a diagnosis of Parkinson’s or other related tauopathies and synucleinopathies.

For millions of individuals currently navigating the disruptive symptoms of obstructive sleep apnea, the message from the medical community is clearer than ever. Beyond restoring restful nights and daytime vitality, committing to nightly respiratory therapy may serve as an essential shield for the aging brain, offering a tangible pathway toward long-term neurological preservation.